Physician profile
Anil Harsh
NPI 1811978554
$848.07
in general payments reported to CMS, 2019-2025
12 companies · $117 in 2025
The $117 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $123 · 2021: $84.44 · 2022: $201 · 2023: $28.17 · 2024: $185 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $330.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $193.46 | 2019-2023 | Bexsero |
| Corium, LLC | $120.26 | 2022-2025 | Azstarys |
| Sanofi Pasteur INC. | $114.23 | 2019-2024 | |
| Novo Nordisk INC | $111.56 | 2024 | |
| Ironshore Pharmaceuticals INC. | $61.85 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $53.10 | 2021-2023 | Vaxneuvance, M-M-R II, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $49.05 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.32 | 2025 | Lifevest |
| Pfizer INC. | $34.11 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.72 | 2020 | |
| Supernus Pharmaceuticals, INC. | $21.06 | 2024 | Qelbree |
| Genentech USA, INC. | $18.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Harsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.